- Home
- CERO vs APVO Comparison
CERO vs APVO Comparison
Compare CERO & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CERO
- APVO
- Stock Information
- Founded
- CERO 2017
- APVO 2016
- Country
- CERO United States
- APVO United States
- Employees
- CERO N/A
- APVO N/A
- Industry
- CERO
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- CERO
- APVO Health Care
- Exchange
- CERO Nasdaq
- APVO Nasdaq
- Market Cap
- CERO 8.4M
- APVO 5.4M
- IPO Year
- CERO N/A
- APVO N/A
- Fundamental
- Price
- CERO $0.99
- APVO $2.36
- Analyst Decision
- CERO
- APVO Strong Buy
- Analyst Count
- CERO 0
- APVO 1
- Target Price
- CERO N/A
- APVO $296.00
- AVG Volume (30 Days)
- CERO 183.5K
- APVO 47.0K
- Earning Date
- CERO 03-18-2025
- APVO 05-07-2025
- Dividend Yield
- CERO N/A
- APVO N/A
- EPS Growth
- CERO N/A
- APVO N/A
- EPS
- CERO N/A
- APVO N/A
- Revenue
- CERO N/A
- APVO N/A
- Revenue This Year
- CERO N/A
- APVO N/A
- Revenue Next Year
- CERO N/A
- APVO N/A
- P/E Ratio
- CERO N/A
- APVO N/A
- Revenue Growth
- CERO N/A
- APVO N/A
- 52 Week Low
- CERO $1.26
- APVO $2.37
- 52 Week High
- CERO $376.00
- APVO $209.38
- Technical
- Relative Strength Index (RSI)
- CERO 29.16
- APVO 28.80
- Support Level
- CERO $1.26
- APVO $3.02
- Resistance Level
- CERO $1.54
- APVO $4.00
- Average True Range (ATR)
- CERO 0.14
- APVO 0.27
- MACD
- CERO 0.07
- APVO -0.03
- Stochastic Oscillator
- CERO 1.63
- APVO 0.00
About CERO CERo Therapeutics Holdings Inc. Common Stock
CERo Therapeutics Holdings Inc is an innovative immunotherapy company advancing the development of next-generation engineered T-cell therapeutics for the treatment of cancer. Its proprietary approach to T cell engineering, which enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, is designed to engage the body's full immune repertoire to achieve optimized cancer therapy.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage, research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidate, APVO436, and preclinical candidates, ALG.APV-527 and APVO603, were developed using ADAPTIR modular protein technology platform. The versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.